Dordaviprone

Dordaviprone
Clinical data
Trade names	Modeyso
Other names	ONC-201
License data	US DailyMed: Dordaviprone;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one;
CAS Number	1616632-77-9;
PubChem CID	73777259;
DrugBank	DB14844;
ChemSpider	30904994;
UNII	9U35A31JAI;
KEGG	D12733;
ChEBI	CHEBI:232328;
ChEMBL	ChEMBL4297310;
Chemical and physical data
Formula	C24H26N4O
Molar mass	386.499 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5;
	InChI InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3; Key:VLULRUCCHYVXOH-UHFFFAOYSA-N;

Dordaviprone, sold under the brand name Modeyso is a medication used for the treatment of diffuse midline glioma (a type of brain tumor). It is dopamine receptor D2 antagonist and an allosteric activator of the mitochondrial caseinolytic protease P.^[1]

Dordaviprone was approved for medical use in the United States in August 2025.^[2] It is the first approval of a systemic therapy for H3 K27M-mutant diffuse midline glioma by the US Food and Drug Administration.^[2]

Medical uses

Dordaviprone is indicated for the treatment of people with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.^[2]

References

^ Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, et al. (December 2020). "ONC201 and imipridones: Anti-cancer compounds with clinical efficacy". Neoplasia. 22 (12). New York, N.Y.: 725–744. doi:10.1016/j.neo.2020.09.005. PMC 7588802. PMID 33142238.
^ ^a ^b ^c "FDA grants accelerated approval to dordaviprone for diffuse midline glioma". U.S. Food and Drug Administration (FDA). 6 August 2025. Retrieved 7 August 2025. This article incorporates text from this source, which is in the public domain.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[pmid33142238-1] Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, et al. (December 2020). "ONC201 and imipridones: Anti-cancer compounds with clinical efficacy". Neoplasia. 22 (12). New York, N.Y.: 725–744. doi:10.1016/j.neo.2020.09.005. PMC 7588802. PMID 33142238.

[FDA_20250806-2] "FDA grants accelerated approval to dordaviprone for diffuse midline glioma". U.S. Food and Drug Administration (FDA). 6 August 2025. Retrieved 7 August 2025. This article incorporates text from this source, which is in the public domain.

[1]

[2]